Mar 15, 06:10 PM

FDA Advisory Committees Support Expanded Use of CAR-T Therapies from Bristol Myers Squibb and Johnson & Johnson Despite Safety Concerns

FDA advisory committees have supported the expanded use of CAR-T therapies, including those from Bristol Myers Squibb and Johnson & Johnson, for blood cancer treatment despite safety concerns. The FDA flagged risks of early death from adverse events but acknowledged the benefits of these therapies in treating multiple myeloma and chronic lymphocytic leukemia.

#FDA #Bristol Myers Squibb

Written with ChatGPT (GPT-3).